These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24937555)

  • 21. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.
    Goodwin G; Fleischhacker W; Arango C; Baumann P; Davidson M; de Hert M; Falkai P; Kapur S; Leucht S; Licht R; Naber D; O'Keane V; Papakostas G; Vieta E; Zohar J
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):520-32. PubMed ID: 19411165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapeutic alliance, a stake in schizophrenia].
    Charpentier A; Goudemand M; Thomas P
    Encephale; 2009 Feb; 35(1):80-9. PubMed ID: 19250998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia].
    Faludi G
    Neuropsychopharmacol Hung; 2005 Mar; 7(1):22-7. PubMed ID: 16167464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How do socio-demographic and clinical factors interact with adherence attitude profiles in schizophrenia? A cluster-analytical approach.
    Beck EM; Cavelti M; Wirtz M; Kossowsky J; Vauth R
    Psychiatry Res; 2011 May; 187(1-2):55-61. PubMed ID: 21074860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Choosing antipsychotic maintenance therapy--a naturalistic study.
    Tavcar R; Dernovsek MZ; Zvan V
    Pharmacopsychiatry; 2000 Mar; 33(2):66-71. PubMed ID: 10761822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relapse and rehospitalization: comparing oral and depot antipsychotics.
    Schooler NR
    J Clin Psychiatry; 2003; 64 Suppl 16():14-7. PubMed ID: 14680414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of treatment acceptability to patients.
    Naber D; Kasper S
    Int J Psychiatry Clin Pract; 2000; 4(1):25-34. PubMed ID: 24927307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Relationships between insight and medication adherence in subjects with psychosis].
    Droulout T; Liraud F; Verdoux H
    Encephale; 2003; 29(5):430-7. PubMed ID: 14615692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drugs for schizophrenia: an update for family physicians.
    Amadio PB; Cross LB; Amadio P
    Am Fam Physician; 1997 Sep; 56(4):1149-56, 1159-60. PubMed ID: 9310066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of partial compliance.
    Marder SR
    J Clin Psychiatry; 2003; 64 Suppl 16():3-9. PubMed ID: 14680412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained drug delivery optimizes long-term treatment of patients with schizophrenia.
    Chue PS; D'Hoore P; Michael Ramstack J
    Acta Neuropsychiatr; 2004 Dec; 16(6):319-25. PubMed ID: 26984545
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atypical Antipsychotic Use in the Treatment of Psychosis in Primary Care.
    Leo RJ; Regno PD
    Prim Care Companion J Clin Psychiatry; 2000 Dec; 2(6):194-204. PubMed ID: 15014629
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective study of the role of long-acting injectable antipsychotics in preventing rehospitalization in early psychosis with cannabis use.
    Rozin E; Vanaharam V; D'Mello D; Palazzolo S; Adams C
    Addict Behav Rep; 2019 Dec; 10():100221. PubMed ID: 31828200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.
    Haddad PM; Brain C; Scott J
    Patient Relat Outcome Meas; 2014; 5():43-62. PubMed ID: 25061342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients.
    Moritz S; Peters MJ; Karow A; Deljkovic A; Tonn P; Naber D
    Ment Illn; 2009 Oct; 1(1):e2. PubMed ID: 25478082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review.
    Masand PS; Roca M; Turner MS; Kane JM
    Prim Care Companion J Clin Psychiatry; 2009; 11(4):147-54. PubMed ID: 19750066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. We need to talk about depot: effect of Community Treatment Order on depot antipsychotic medication compliance.
    Suetani S; Foo E; Wilson D
    Australas Psychiatry; 2014 Aug; 22(4):357-359. PubMed ID: 24919833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perception of depot antipsychotics by mental health professionals.
    Lambert T; Brennan A; Castle D; Kelly DL; Conley RR
    J Psychiatr Pract; 2003 May; 9(3):252-60. PubMed ID: 15985940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.